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Abstract: Inherited platelet disorders (IPDs) are rare diseases featured by low platelet count and
defective platelet function. Patients have variable bleeding diathesis and sometimes additional
features that can be congenital or acquired. Identification of an IPD is desirable to avoid misdiagnosis
of immune thrombocytopenia and the use of improper treatments. Diagnostic tools include platelet
function studies and genetic testing. The latter can be challenging as the correlation of its outcomes
with phenotype is not easy. The immune-morphological evaluation of blood smears (by light- and
immunofluorescence microscopy) represents a reliable method to phenotype subjects with suspected
IPD. It is relatively cheap, not excessively time-consuming and applicable to shipped samples. In some
forms, it can provide a diagnosis by itself, as for MYH9-RD, or in addition to other first-line tests as
aggregometry or flow cytometry. In regard to genetic testing, it can guide specific sequencing. Since
only minimal amounts of blood are needed for the preparation of blood smears, it can be used to
characterize thrombocytopenia in pediatric patients and even newborns further. In principle, it is
based on visualizing alterations in the distribution of proteins, which result from specific genetic
mutations by using monoclonal antibodies. It can be applied to identify deficiencies in membrane
proteins, disturbed distribution of cytoskeletal proteins, and alpha as well as delta granules. On
the other hand, mutations associated with impaired signal transduction are difficult to identify
by immunofluorescence of blood smears. This review summarizes technical aspects and the main
diagnostic patterns achievable by this method.
Keywords: inherited platelet disorders; hereditary thrombocytopenias; blood smear; immunofluorescence;
bleeding tendency
1. Introduction
1.1. Inherited Platelet Disorders
Inherited platelet disorders (IPDs) are a group of rare diseases characterized by reduced platelet
numbers and impaired platelet function, causing variable bleeding diathesis. They can affect only
platelets, present with other congenital features (syndromic forms), or confer the risk to develop over
time additional manifestations such as nephropathy or hematological malignancies (predisposing
forms) [1].
The landscape of IPDs comprises, in early 2020, more than 30 disorders and 50 genes. Particularly
with the development of high-throughput sequencing tools, the list of IPDs has become enriched rather
rapidly [2–8].
In IPDs, at least one of the three main phases of platelet biogenesis is impaired [9]. The genetic
defect can alter the differentiation of hematopoietic stem cells into megakaryocytes (Mks), as in
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congenital amegakaryocytic thrombocytopenia (CAMT), due to biallelic mutations in the gene
coding of the receptor for thrombopoietin (TPO) MPL causing major deficiency or even absence
of Mks in the bone marrow [10]. Mutations in transcriptional regulators, such as RUNX1 or ETV6,
hit Mk maturation and perturb hematopoietic precursors leading to thrombocytopenia, impaired
platelet function, and increased risk of clonal hematopoiesis [11–14]. Alterations in cytoskeletal
proteins, such as non-muscular myosin IIA, β1-tubulin, alpha (α) 1-actinin or filamin A, target the
phase of platelet formation and release into blood vessels. In these forms, platelets are typically
reduced in number and increased in size [15–18]. Finally, some IPDs induce thrombocytopenia
by reducing the platelet life span, such as changes in glycosylation due to a mutated glucosamine
(UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE) gene; or impaired function of the
ubiquitination, proteasome system in ANKRD26-related thrombocytopenia (ANKRD26-RT) [19–22].
1.2. Bleeding Symptoms do not Allow Specific Diagnosis of an IPD
From a clinical point of view, IPDs are characterized by highly variable bleeding tendency.
The hemorrhagic history of patients with platelet function defects is significantly more severe than
that of patients with thrombocytopenia only, who sometimes present with no bleeding at all. Most
affected individuals do not have a spontaneous hemorrhage, but may develop bleeding complications
in case of hemostatic challenges such as traumas or surgery. When present, spontaneous bleedings are
prevalently muco-cutaneous (e.g., easy bruising, epistaxis, gum bleeding, menorrhagia, gastrointestinal
bleeding) and rarely serious [23]. When a hemorrhagic phenotype is overt, the kind of symptoms may
help to differentiate “IPD-” from “non-IPD-bleeding-subjects” (e.g., having coagulopathies). In contrast,
this criterion is fairly useless in distinguishing among diverse IPDs as symptomatic patients commonly
share prevalently mucocutaneous hemorrhages [23].
Apart from a few exceptions, the platelet count in IPDs is stable during life, unless additional
causes for thrombocytopenia are acquired. In the absence of compromised platelet function, the severity
of bleeding tendency primarily depends on the platelet count [1]. Lifelong bleeding history, female sex,
and some types of interventions (e.g., cardiovascular or urological procedures associate with a higher
risk of hemorrhagic complications) predict the individual risk of bleeding at surgery [24].
1.3. Non-Platelet Features Clinically Characterize some IPDs
Some IPDs present with congenital defects depicting peculiar syndromic pictures. For instance,
skeletal defects lead to pathognomonic deformations in Thrombocytopenia-absent radius syndrome
(TAR) or Radioulnar synostosis with amegakaryocytic thrombocytopenia (RUSAT) [25,26]. Eczema
and mild-to-severe immunodeficiency associate with Wiskott–Aldrich syndrome (WAS) and X-linked
thrombocytopenia (XLT), respectively [27,28]. Red blood cell (RBC) thalassemic-like abnormalities are
typically found in GATA1-related thrombocytopenia (GATA1-RT) [29], while Stormorken- and York
platelet syndrome share the finding of congenital myopathy [30,31].
“Predisposing IPDs” make patients prone to develop, during life, additional manifestations hitting
different systems. With regard to the most prevalent MYH9-related disease (MYH9-RD), the affected
subjects can manifest sensorineural deafness, nephropathy, juvenile cataracts, and elevation of liver
enzymes. The individual risk of such features depends on the location of the mutation, which differently
affects protein function [32]. A risk for deafness is also present in patients with macrothrombocytopenia
due to DIAPH1 mutations [33].
Much more relevant for prognosis, all patients with CAMT develop critical bone-marrow aplasia
during infancy [34]. A similar evolution can affect the proportion of patients with RUSAT [26]. A possible
progression to hematological malignancies has been reported in three forms of autosomal dominant
(AD) IPDs with congenital thrombocytopenia with normal-size platelets [35,36]. The proportion of
patients developing myelogenous or lymphoblastic leukemia, or myelodysplastic syndrome, ranges
from less than 10% in ANKRD26-RT to about 25% and 33% in ETV6-related thrombocytopenia
(ETV6-RT) and in Familial platelet disorder with propensity to acute myelogenous leukemia
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(FDP/AML), respectively [12,13,37–42]. A potential onset of juvenile myelofibrosis, splenomegaly,
and osteoporosis has been reported in subjects with mutations in tyrosine kinase SRC (SRC-related
thrombocytopenia) [43].
1.4. Treatment of IPDs is Usually Symptomatic
Hematopoietic stem cell transplantation (HSCT) is indicated for CAMT, WAS, severe phenotypes,
or poor prognosis IPDs; otherwise, treatment is mostly symptomatic [44,45]. Spontaneous and
provoked bleedings can be prevented by simple behavioral norms such as avoiding antiplatelet drugs
and contact sports, providing regular dental care, and reducing menorrhagia with hormonal therapy.
For the therapeutic management of moderate hemorrhage, anti-fibrinolytic agents and desmopressin
are effective options. Only in the case of severe bleeding, platelet concentrates, or pro-hemostatic
compounds, such as recombinant activated factor VII (rFVIIa) are indicated [46–48]. In preparation
for surgical procedures, the increase of platelet number and/or the restoring of platelet function
can be required. Especially in IPDs with defective platelet function, anti-hemorrhagic prophylaxis
is associated with a significant reduction of bleeding frequency [24]. The threshold platelet levels
considered safe to undergo invasive procedures vary according to the kind of hemostatic challenge
(e.g., childbirth, or major surgery), and the severity of platelet dysfunction. In the case of a major
hemostatic challenge in a patient with major platelet dysfunction, platelet transfusion is recommended
independently of the platelet count target [49–51]. However, especially in Glanzmann’s thrombasthenia
(GT), platelet transfusion should be restricted to situations in which other treatments fail to reduce
the risk of alloimmunization of patients against the glycoprotein lacking on their own platelets. To
transiently increase the platelet count, a thrombopoietin-receptor agonist (TPO-RA) may represent an
alternative to platelet concentrates in a subgroup of IPDs [52,53]. Only in WAS, splenectomy represents
an option to increase platelet count. Splenectomy should not, however, be adopted in patients who are
candidates for HSCT as it worsens the disease-related immunodeficiency [54]. Valid alternatives for
these subjects are gene therapy, or TPO-RAs [55,56]. Effective strategies to cure extra-hematological
features of MYH9-RD, such as renin-angiotensin pathway inhibitors to slow nephropathy progression,
or cochlear implantation to overcome profound deafness, have become available during the last decade
for patients at risk for these complications [57,58].
1.5. Current Diagnostic Tools for IPDs
IPDs are suspected when there is an unusual bleeding history and/or other phenotypic clues
are present. When other affected relatives are present, or peculiar syndromic features are detectable,
the diagnosis of an IPD can be made relatively easily. However, identification of the altered platelet
structure is usually very challenging. On the other hand, the lack of inheritance trait does not exclude
IPDs. Indeed, sporadic cases by de novo mutations or mosaicism have been reported in more than
one-third of patients with MYH9-RD, one of the less rare IPDs [59].
Besides clinical evaluation, including the documentation of hemorrhagic history using a validated
assessment tool, such as the ISTH Bleeding Assessment Tool (ISTH-BAT) [23,60], the first diagnostic
step for IPDs requires an estimation of platelet size [61], light-transmission aggregometry (along
with the evaluation of dense granule release by lumiaggregometry), and flow cytometry. Generally,
only selected patients undergo, in the first instance, further sophisticated investigations like western
blotting, electron microscopy, or the measurement of certain enzyme activity [62]. These platelet
function assays have several shortcomings. Globally, the level of standardization of such assays is low.
In addition, relatively large amounts of fresh blood are required, which makes it impossible to ship
samples, and requires patients to be at the place of analysis. For aggregometry, a minimum of platelet
concentration (i.e., not less than 80 × 103 per µl) is required within platelet-rich plasma or whole blood
for effective analysis [63–65]. This can pose a challenge when dealing with patients having moderate
or severe thrombocytopenia. Additionally, the collection of large volumes of blood is not possible from
neonates and young children.
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Genetic analysis has taken a big leap forward during the last ten years. The spread of
next-generation sequencing (NGS) greatly contributed to the unraveling of the genetic basis of
several forms of IPD, and thus immediately became a significant diagnostic tool in the field. Using a
small amount of blood with minor risk of pre-analytical artifacts, it can provide patients with a highly
accurate diagnosis [4–7,66–72]. As it becomes cheaper to perform, it is not inconceivable that NGS
could become the standard above other diagnostic techniques. However, interpretation of genetic
findings can be difficult especially in patients without a peculiar clinical picture. In fact, NGS usually
detects many variants of unknown or uncertain significance, whose correlation with the patient’s
phenotype is unresolved, and over-interpretation is a major risk [73–77]. Data from big case series
reported so far indicated that NGS is able to achieve a diagnosis in nearly 50% of IPD patients suffering
from congenital thrombocytopenia, and in nearly 25% of those with inherited platelet function disorder.
Taken together, these data show that the probability of achieving a definite diagnosis by NGS is very
high in selected and well-characterized individuals, but the underlying molecular cause of an IPD may
still not be identified in a large number of patients.
1.6. Main Advantages of Blood Smear Analysis
In such a landscape, the immune-morphological analysis of platelets on the blood smear may
represent a key approach in the work-up of IPDs both for feasibility and diagnostic power for the
following reasons: first, it requires a low volume of blood (less than 100 µl), thus is easily collected
even from newborns [78]. Secondly, samples can be shipped safely, even long distances, to reach the
diagnostic reference centers. Thirdly, although requiring specialized expertise, it is relatively cheap
and not excessively time-consuming. For instance, at our Institute, the overall procedure (including
staining and assessing the blood smears for a large panel of markers) takes about 45 min per patient.
Fourthly, the immune-morphological evaluation of blood smears allows more detailed phenotyping of
the platelets [79]. The double-analysis approach (i.e., by light- and immunofluorescence-microscope,
see below) can provide diagnosis by itself, as in the case of MYH9-RD, or in addition to other first-line
tests such as aggregometry and flow cytometry as for GT and its variants (type 2- and type 3 GT), or
for classical and monoallelic Bernard–Soulier syndrome (BSS) [80–83]. In addition, it can indicate for
clinicians that the patient may have an increased risk for bleeding during interventions, as in the case of
major alterations in α- or dense granule content (i.e., Grey Platelet Syndrome, GPS, α-,δ-, or α+δ storage
pool disease, SPD) [62,84]. By labeling a few proteins, a potential abnormality could be identified
or narrowed-down to a group of IPDs featured by cytoskeleton alterations (e.g., FLNA-related
thrombocytopenia, FLNA-RT [17], TUBB1-related thrombocytopenia, TUBB1-RT [85], and WAS).
Likewise, it is possible to differentiate between GPS and GFI1B-related thrombocytopenia (GFI1B-RT),
in the case of large and pale staining platelets in the May-Grünwald Giemsa (MGG) blood smear. Both
have major deficiencies in α-granule proteins, but only GFI1B-RT platelets express the stem cell antigen
CD34 [86].
An international study that involved 3217 patients referred to four major specialized centers
demonstrated that double-stained blood smear analysis was able to achieve a diagnosis of IPD
(confirmed by parallel genetic testing and standard laboratory tools) in 27% of the referred subjects.
This proportion was equivalent to those achieved in the major previous case series, where all the
available diagnostic tools, including those requiring a larger amount of blood, were exploited [78].
2. Technical Considerations
2.1. Preparation of Blood Smears
Either capillary blood, obtained by finger-prick, or anticoagulated blood can be used for the
preparation of blood smears. In the latter case, the choice of ethylenediaminetetraacetic acid (EDTA) is
advisable with respect to other anticoagulants (e.g., citrate, or hirudin) since it proved to maintain
superior stability of immune-morphological markers [87]. When using anticoagulated blood, slides
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should be prepared as soon as possible (within 4 h) after drawing to avoid the increase of platelet
size due to low calcium concentration. Since the marginal band of microtubules depolymerizes at
low temperatures, leading to alteration of the discoid platelet shape, the blood should be stored at
temperatures > 20 ◦C [88].
The blood smear preparation is relatively simple. When correctly executed, blood films are stable
for several days and can be shipped by regular mail even over long distances. The slides should be
preferably prepared by skilled persons, by following a few simple recommendations. Glass slides
have to be clean and fat-free. An about 3–4 µL blood drop is placed on the base-slide 1 cm from the
edge. The spreader-slide, inclined at an angle of about 40 degrees, is then placed on the base slide,
ahead of the drop, and pulled back to make contact with blood. As soon as the drop has spread
out along the line of contact, the smear is obtained by rapidly moving towards the spreader-slide.
The ideal length of the smear is 2/3 of that of the base-slide. To form a cell-monolayer, the ideal smear
has to be neither too thin nor too thick. Thickness depends on the dimension of the blood drop,
the angle of the spreader-slide, and the speed of the spreading. The lateral edges and an oval-shaped
tail should be visible (Figure 1). Once smeared, the slides should be immediately air-dried [89].
A You-Tube instruction on how to make the blood smears is available under the following link:
https://www.youtube.com/watch?v=BbBcWp5LAXs.
Artefactual alterations of platelets or leukocytes on the smear can be induced by hemolysis due to
moisture precipitation occurring during air freight when a cool glass slide comes into contact with
warm, humid air. Hence, it is recommended to wrap the slides before shipment.
At least 15 to 20 slides should be collected from each patient, as typically only two colors per slide
(red and green = two different antibodies) are used for immunofluorescence staining.
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2.2. Immunofluorescence Labelling
Immunofluorescence staining and analysis are usually performed in specialized laboratories.
Nevertheless, referring physicians should take into account that slides should ideally be fixed within
three days after film preparation, and the timing of shipment has to be planned accordingly.
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Before immunofluorescence staining, slides undergo fixation using different methods according
to the protocol in use in the laboratory. The main options are ice-cold acetone (−20 ◦C; 2–5 min,
permeabilizing), or methanol (−20 ◦C, 1 min, permeabilizing), or 1–3% paraformaldehyde (room
temperature for 10–20 min, followed by permeabilization with 0.1–0.2% Triton X-100 for 5–10 min).
After fixation and permeabilization, blood smears are covered with monoclonal or polyclonal antibodies
against the target proteins [78]. Fluorescence can be obtained by antibodies directly conjugated with
a fluorescent dye, or by secondary antibodies labeled with fluorescent dyes that bind to primary
antibodies. By staining in parallel the target protein (e.g., MYH9) and another platelet-specific marker
(e.g., β1-tubulin), easy identification of the distribution of the protein of interest can be achieved.
To counterstain nuclei, Hoechst or 4′, 6-diamidino-2-phenylindole (DAPI) are commonly used. It is
highly advisable to always stain for two platelet structures. Otherwise, the interpretation becomes
very difficult if a protein is missing. The expression pattern of the target proteins is then detected by
comparison with a normal control smear stained in parallel.
2.3. Note of Caution
Although binding to the same protein, different monoclonal antibodies differ in their avidity and
binding strength. Especially for quantitative assessment, appropriate controls and quality measures
are mandatory. In addition, the absence of binding of a monoclonal antibody does not prove the
absence of the protein. In the case of a polymorphism of the gene affecting only the binding site of the
monoclonal antibody, the protein may be present despite the antibody, not binding.
3. Main Diagnostic Patterns
3.1. Light Microscopy
MGG- or Wright-stained blood film analysis represents the first step of the differential diagnosis of
IPDs on a blood smear. First, it allows an estimate of the platelet count, which can be underestimated
by automated cell counters in patients with platelet macrocytosis [90]. Second, it enables the evaluation
of platelet size and platelet staining. In addition, light microscopy can identify morphological
abnormalities of other blood cells, which can guide the diagnostic work-up. Conventionally, at least
100 platelets (and other blood cells) per smear should be observed.
3.2. Platelet Size
The assessment of the mean platelet diameter (MPD) is a key step of the differential diagnosis
of IPDs. It can be achieved by an ocular micrometer or by software-assisted image analysis. A
collaborative study on a large series of subjects with 19 different disorders proposed a classification of
IPDs according to platelet diameter. Namely, it distinguished forms with enlarged (MPD > 3.2 µm),
decreased (MPD < 2.6 µm), and normal (2.6 µm < MPD < 3.2 µm) MPD [61]. Particularly, the finding
of MPD > 3.9 µm (corresponding to about half the diameter of a normal red blood cell) or < 2.6 µm
showed good sensitivity and specificity in differentiating IPDs with giant platelets (i.e., MYH9-RD and
BSS) from those with small platelets (i.e., TAR, CAMT, and WAS/XLT), respectively. An example of
normal and altered platelet dimensions is shown in Figure 2, Panel I.
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3.3. Platelet Staining
The presence of azurophilic granules (e.g., platelet α-granules) determines the typical eosinophilic
aspect of platelets. A reduction of platelet staining can suggest at least three forms of IPDs with
thrombocytopenia and normal-to-enlarged platelet size. In GPS, the prototypical form of this group,
α-granules are almost completely absent, and platelets appear large and empty [84]. In GFI1B-RT or
GATA1-RT, a partial reduction of granularity making platelets “pale” can be detected [91,92]. Regarding
α-, δ- or α+δ SPD, only in the case of a severe reduction of α-granules will platelets appear less stained
by light microscopy. An example of normal and reduced platelet staining is shown in Figure 2, Panel II.
3.4. Other Morphological Alterations of Platelets
The presence of platelet clumps (Figure 2, Panel II), despite the best efforts to avoid platelet
activation during blood-letting and preparation of blood smears, can suggest type 2B- or platelet-type
von Willebrand disease (vWD) [93,94]. In the latter, platelets are often enlarged [95].
The presence of giant α-granules can indicate Thrombocytopenia Paris-Trousseau (TCPT) [96].
Prominent vacuoles can be observed in the platelets of patients affected by GATA1-RT [97].
Note of caution: the most frequent reasons for platelet aggregates on the blood smear is the use
of blood from a finger prick or the time taken between dropping the 3 µL of blood onto the slide
and creating the smear was too long resulting in the activation of platelets through contact with the
glass surface.
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4. Morphological Alterations of Other Blood Cells
When dealing with large platelets, the “reader” of the blood smear should carefully look for possible
basophil inclusions in neutrophils’ cytoplasm, which are pathognomonic in MYH9-RD [96]. It has to be
taken into account that the so-called “Döhle-like” bodies, always identifiable by immunofluorescence,
are detectable only in a proportion of the affected patients by light microscopy (see below).
Among subjects with pale platelets, the finding of red blood cell (RBC) anisopoichilocytosis (i.e.,
cells having prominent differences in size and shape) can corroborate the suspicion of GATA1-RT [97].
The presence of erythrocytes resembling a mouth (i.e., stomatocytes) plus platelet macrocytosis can
indicate sitosterolemia (STSL-RT) [98].
In regard to RBCs, microcytosis and hypochromia are often detectable in symptomatic IPD
patients, independently on their specific form, because of bleeding-related iron deficiency anemia.
4.1. Immunofluorescence Microscopy
Immunofluorescence analysis represents the second step of the differential diagnosis of IPDs on a
blood smear. Several platelet proteins, belonging to different categories (see below) can be labeled
by antibodies. Based on clinical features (e.g., hereditary trait, presence of syndromic picture) or
morphological aspects (e.g., enlarged or small platelets), a proper panel of antigens to be tested can be
defined. Another approach is to use a standard minimum-panel for all the patients under investigation,
to be probably integrated as a second step with further staining or other diagnostic tests. This latter
approach allows us to gain more information and to provide a guidance answer more rapidly. Most
important, it allows the blood smear reader to gain experience of how certain platelet structures are
altered in various IPDs.
4.2. Cytoskeleton Proteins
A considerable group of IPDs are characterized by alterations in cytoskeleton proteins, reducing
platelet production, and altering platelet size.
The platelet cytoskeleton often shows alterations in various IPDs associated with platelet
macrocytosis as well as in acquired platelet disorders. In addition, it can be an artifact in case
of platelet pre-activation or cold storage of the blood tube before preparing the smear.
Abnormal distribution of the MYH9 coded protein non-muscular myosin IIA heavy chain in the
cytoplasm of neutrophils drives the diagnosis of MYH9-RD with high sensitivity and specificity [96].
The pathognomonic inclusions, not always detectable in the MGG-stained blood smear, are usually
evident in immunofluorescence (Figure 3, Panel I). At least two main patterns have been described.
The one is typical for mutations involving the tail domain of non-muscular myosin IIA and consists of
one-to-three large (2–5 µm) aggregates per cell together with further small aggregates. Conversely,
mutations involving the head domain of the protein produce several smaller (<0.5 µm) aggregates.
Not all leukocytes may express these inclusion bodies, especially in the case of a genetic mosaic of
the patient.
Double labeling for cytoskeleton markers β1-tubulin and filamin A enables to recognize patterns
suggestive for two forms of IPD with large, normal-stained platelets: TUBB1-RT and FLNA-RT [17,85].
TUBB1-RT is characterized by the loss of the typical peripheral ring of β1-tubulin, which forms images
similar to balls of yarn (Figure 3, Panel II).
In FLNA-RT, up to one-half of platelets are lacking filamin A staining, while displaying the normal
β1-tubulin distribution. Another typical feature of FLNA-RT we have observed in our laboratory is
diffuse staining of platelets for filamin A, which usually appears as a thick ring (Figure 3, Panel III).
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Figure 3. Cytoskeleton markers. Panel I. MYH9-RD. (A) A normal-stained giant platelet and (B) a faint
blue Döhle-like body in a neutrophil’s cytoplasm of an MYH9-RD patient, by light microscopy. (C) The
aggregates of mutated non-muscular myosin II-A heavy chain can be unrecognizable in May-Grünwald
Giemsa (MGG)-st ined slides, while they are al ays detectable by immunofluorescence microscopy. (F)
In the control, the non-muscular myosin II-A heavy chain signal is diffuse, while in the affected subjects
it forms aggregates of different sizes and numbers. (D) Few, large (2–5 µm) inclusions are typically
observed in patients with mutations hitting the tail domain of MYH9 coded protein. (E) Multiple,
smaller (<0.5 µm) aggregates are characteristic of patients carrying mutations in the head domain of
the same protein. Panel II. TUBB1-related thrombocytopenia (TUBB1-RT). (A) An MGG-stained blood
smear of an affected subject displaying large, normal-stained platelets. (B,C) In immunofluorescence,
the typical β1-tubulin ring (control) is disrupted and resembles a ball of wool. Panel III. FLNA-related
thrombocytopenia (FLNA-RT). A) Patients suffering from FLNA-RT have macro-thrombocytopenia with
normal granular staining of platelets. (B–D) By immunofluorescence microscopy, filamin A presents
altered distribution with respect to the typical peripheral ring-shaped signal (control). In the affected
subjects, the filamin A pattern can appear diffused or patched. Panel IV. WAS. (A) Patients distinctively
show small platelets in the MGG-stained blood smear. (B–D) The genetic alterations make platelet
cytoskeleton stiffer, thus causing an abnormal distribution of β1-tubulin by immunofluorescence
assessment. With respect to the typical ring (control), it can present stretched or bent.
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The use of an antibody against β1-tubulin is also worthwhile to identify some patients with
WAS [78]. In this disorder, platelets are reduced in size and may show the abnormal distribution of this
cytoskeleton protein that appears stretched or forming uncommon images (e.g., eight-shaped aspect)
(Figure 3, Panel IV). However, not all WAS patients show these changes in β1-tubulin, and a normal
β1-tubulin ring does not exclude WAS.
4.3. Surface Receptors
Two IPDs can be readily identified by labeling proteins belonging to the membrane receptor
complex GpIb/IX/V or GpIIb/IIIa [78].
Patients with biallelic BSS display complete or severe depletion of GpIb/IX (Figure 4, Panel
I). Monoallelic form of BSS, having a partial reduction of these glycoproteins, can be sometimes
suspected by immunofluorescence. However, immunofluorescence analysis on the blood smear is at
best semiquantitative, and reduced surface Gp expression requires confirmation by flow cytometry.
Similarly, in “classic” GT platelets are normal in number and size, but the expression of GpIIb/IIIa
on the surface is abolished or severely reduced (Figure 4, Panel II). Only in type 3 (i.e., monoallelic),
GT platelets are often enlarged. Immunofluorescence can also reveal a partial reduction of GpIIb/IIIa
in type 2 or 3 GT (see comment above).
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Labeling for von Willebrand factor (vWF), thrombospondin (TS), and P-selectin (P-sel) enables 
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Figure 4. Surface protein markers. Panel I. Bernard–Soulier syndrome (BSS). (A) Light microscopy.
A patient affected with biallelic BSS displays a large platelet on MGG-stained blood smear. (B,C)
Immunofluorescence microscopy. By labeling for GpIbα (green) and vWF (red), the green signal is
completely abolished in the patient due to the absence of the corresponding protein on the surface of
platelets. Panel II. GT. (A) Normal-size platelets in a subject affected with GT, by light microscopy. (B,C)
In immunofluorescence, complete and partial reduction of the GpIIb/IIIa signal (green) in two patients
with respect to control. Note of caution. Although the immunofluorescence pictures are taken by the
green-light channel, a dim red signal emerges in some pathologic samples due to counterstaining for a
second marker in red (in this case, MYH9).
4.4. Alpha and Delta Granule Markers
Labeling for von Willebrand factor (vWF), thrombospondin (TS), and P-selectin (P-sel) enables to
detect the lack of α-granules, thus confirming GPS [78]. Partial depletion of α-granules can refer to
two IPDs with a low number of normal or enlarged platelets: GATA1-RT and GFI1B-RT. These forms
can be further distinguished in the presence of dyserythropoiesis or by the expression of the stem cell
J. Clin. Med. 2020, 9, 539 11 of 20
antigen CD34 on platelets, respectively [86] (Figure 5). In the absence of thrombocytopenia, a decrease
of α-granule markers moves towards α-SPD (Figure 6, Panel I).
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Figure 5. GFI1B-RT. (A) GFI1B-related thrombocytopenia (GFI1B-RT) is characterized by large and pale
platelets, by light microscopy. (B–G) The reduction of azurophilic granules’ content can be confirmed
in immunofluorescence by staining the typical alpha-granule markers such as von Willebrand factor
(vWF) or P-selectin (P-sel) that appear reduced with respect to control. Of note, platelets also present
CD34 stem cell antigen that is normally not expressed in the controls.
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Figure 6. lpha- and delta storage pool disease (SPD) by immunofluorescence microscopy. Panel I.
(A–F) In alpha SPD, the labeling for the alpha-granule markers thrombospondi (TS), P-selectin (P-sel),
and von Willebrand factor (vWF) shows significantly reduced staining with respect to control. Pa el II.
(A–F) In delta SPD, the dense granul m rkers L mp 1 (L1), Lamp 2 (L2), and CD63 isplay iffuse
patterns with reduced or even absent granularity. Alpha- and delta SPD can present associated.
A set of dense granule markers as Lamp 1 (L1), which is present also in the lysosomes, Lamp 2
(L2), and CD63, allows identifying forms with δ-granules reduction, δ-SPD (Figure 6, Panel II). If the
patient also presents with oculo-cutaneous albinism Hermansky–Pudlak syndrome is the most likely
diagnosis. Abnormalities of δ-granule distribution associated with mild thrombocytopenia suggest
another IPD, which will be discussed below (i.e., ETV6-RT). Finally, it should be recalled that either
acquired platelet defects or preanalytical platelet activation can result in alterations of the distribution
of granule markers.
Note of caution. The main pathologic patterns of IPDs reported in Figures 3–6 were obtained by
a regular immunofluorescence microscope. By exploiting more sophisticated technologies, such as
confocal microscopy, one can achieve higher quality images, as shown, as an example, in Figure 7. It
allows us to get better definition and counterstain and to visualize the specific distribution of platelet
markers more clearly. In contrast, only a few centers have a confocal microscope available, and the time
to obtain the images is longer and not feasible for diagnostic purposes. Since the aim of this review is
to guide physicians in the diagnostic work-up of IPDs, we deliberately decided to present primarily
J. Clin. Med. 2020, 9, 539 12 of 20
images obtained by regular immunofluorescence microscopy. Although the recognition of certain
pathologic patterns can be more difficult, it is more representative of the real-life diagnostic setting.
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Figure 7. Images of pathologic patterns of five forms of inherited platelet disorder (IPD) obtained
by confocal microscopy. Immunofluorescence microscopy. In Glanzmann’s thrombasthenia (GT), platelets
show almost no GpIIb/IIIa surface receptor (green). In BSS, the signal corresponding to GpIb/IX (green)
on the surface is lacking, and only some spots inside the platelets are recognizable, showing the
altered protein which cannot be transferred to the membrane. In GFI1B-RT, the stem cell antigen CD34
(green) persists on the platelet surface. Instead of a typical nice ring (controls), the cytoskeleton marker
β1-tubulin (green) appears twisted in Wiskott-Aldrich syndrome (WAS), and resembles a ball of wool
in TUBB1-RT. The healthy controls are shown in the upper pictures.
5. Weaknesses and Ethical Considerations
5.1. Limitations Related to this Method and New Perspectives
The immune-morphological analysis of blood smears needs skilled operators and can be performed
only in specialized centers. This logistic limitation can be easily ov rcome by shipping samples. With a
view to the future, the possibility of automatic or semi-au omati reading of the immunofluorescence
p ttern is a tractiv as it could mitigat s me logistical difficulties. Si l r automated readers ar
established for routine practice in rheumatology laborator es.
Some preanalytical issues are still debated. First, it has not been c rified whether the smears
obtained by finger prick can lead to artifacts by inducing platelet activation. Similarly, also
EDTA-dependent platelet pre-activation c n alter some morphological p rameters on slide btained
by anticoagu d blood [99]. Moreover, spontaneous activat on can ffect platelet markers, mainl
cytoskeleton proteins (e.g., due to pr analytic lt rations, signaling defects, or IPDs hemselves as type
2B vWD or mon allelic GT). None of the morphological markers of platelet activation can differentiate
between in-viv activation and preanalytical art ifacts.
In regard to th diagnostic power, se sitivity, nd specific ty of the immunofluorescence method
seem to be very high in MYH9-RD [78,96,100,101]. Similar performance parameters were found for GT
and biallelic BSS [78]. Encouraging data have also been reported about the identification capability f
PS by blood smear assessment [84,102]. About th other forms, due to the scarceness of patients,
sensit vit and specificity evalu tion are not achievable yet.
When all immune-mor hological patterns rmal, the present method can provide rapid
help to the differential diagnosis by excluding some IPDs. On the other hand, the global n gative
predictive value is questionable since other acquired or inherited disorders, causing throm ocytopenia
and platelet dysfunction, cann t be xcluded nor suggested.
J. Clin. Med. 2020, 9, 539 13 of 20
To face these limitations, further network studies involving a broader number of patients,
and sharing samples among laboratories, should be encouraged.
New substantial diagnostic perspectives rely on the identification of specific changes in platelet
proteins being recognizable by diagnostic antibodies. A possible diagnostic pattern for ACTN1-related
thrombocytopenia has been proposed upon observing the peculiar distribution of MYH9 protein in the
granulomere area of surface-activated platelets [103]. Besides, alteration in MYH10 distribution has
been reported as a sign of thrombocytopenia due to FLI1 or RUNX1 mutations [104]. On the side of
platelet function defects, the possibility to mark phosphorylated proteins along the major signaling
pathways seems promising to enlarge the diagnostic spectrum of these disorders [43].
5.2. Ethical Considerations
Mainly with the increasing use of NGS, some major ethical issues related to IPDs diagnosis have
arisen. They prevalently concern forms conferring the risk of acquired hematological malignancies
as ANKRD26-RT, ETV6-RT, and FDP/AML. These disorders are largely characterized by mild
thrombocytopenia and minor bleeding tendency. So, at least at the diagnosis stage, their impact on
patients’ quality of life can be almost negligible. In contrast, the additional information about an
increased risk of leukemia can considerably enhance the psychological disease burden of patients and
parents (if the patient is a minor). Notably, the global proportion of patients developing hematological
malignancies is low, with 10 to 30% [12,13,35–42]. Moreover, we do not have at now efficient tools to
predict the individual risk nor to prevent the development of leukemia.
Currently, experts in the field are discussing the implications of testing for IPDs in regard to IPDs
associated with increased risk for hematological malignancies [77,105]. Before undergoing genetic
testing, patients are usually requested to give informed consent, and they can opt not to receive
additional incidental information (e.g., in a female patient, to be a carrier of hemophilia A) [106].
Conversely, in the IPDs setting of ANKRD26-RT, ETV6-RT, and FDP/AML, it is not possible to separate
the diagnostic- from the predictive value of the mutation. Also, immunofluorescence testing can raise
the suspicion at least for ETV6-RT. In eight out of nine patients suffering from this form, detectable
ETV6 proteins within the platelet cytoplasm (absent in the healthy controls) have been reported.
Likewise, dense granule markers L2 and CD63 were diminished and diffusely distributed in ETV6-RT
platelets [107]. Before including antibodies staining for ETV6 into the panel, specific consent should be
obtained from the patient.
6. Conclusions
The diagnostic method to identify IPDs using a blood smear presents a helpful “platform of
action”. It allows rather extended diagnosis in young children using minimal amounts of blood. Blood
smears can be easily prepared even at sites far away from specialized laboratories and can be mailed for
further diagnostic workup. The method powerfully suggests diagnosis in some cases (e.g., MYH9-RD,
GT, and BSS), making it possible to achieve the genetic confirmation restricted to the gene of interest.
A recapitulatory, guidance flow-chart for diagnostic testing for IPDs is shown in Figure 8.
Except a few selected forms, the main benefit of a confirmed diagnosis of IPD is to avoid
over-treatment. In fact, one of the main risks of these patients is to be misdiagnosed as having immune
thrombocytopenia (ITP) or, less frequently, myelodysplastic syndrome. These misdiagnoses seriously
impact their management by exposing patients to ineffective and potentially harmful treatments such
as splenectomy, immunosuppression, or chemotherapy [32,51,108].
To progressively understand IPDs, further characterization of patients is highly relevant.
The combination of genetic testing, together with detailed phenotypic characterization and systems
biology studies in the laboratory are essential. Immunofluorescence analysis of platelets on a blood
smear is one of the new tools contributing to these joint efforts. Moreover, it allows the rapid
translational application of new findings on IPDs obtained by research laboratories using mouse
models and cultured Mks into clinical practice.
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